According to an August 9th report by Reuters news agency, the U.S. Food and Drug administration recently rejected Cephalon Inc. experimental attention deficit disorder drug Sparlon, after a case of Stevens Johnson Syndrome was reported during the clinical trials. An advisory panel to the FDA recommended the drug not be approved due to safety concerns.

It is good to see the FDA taking notice of SJS. However labeling of over the counter ibuprofen products has yet to be changed. Recently the Stevens Johnson Syndrome Foundation received new reports of deaths to these products. Both were 5 year old girls. According to the SJS Survey forms we have had 50 cases of SJS and TEN related to these products. We will continue to work towards a labeling change to include Stevens Johnson Syndrome.

If you or a family member has experienced Stevens Johnson Syndrome and you have not reported your case to the FDA, we are asking that you please complete the FDA online reporting form at: www.fda.gov/medwatch/report/consumer/consumer.htm